Replies to post #320707 on Avid Bioservices Inc (CDMO)

[north40000]

Your question that I asked originally at Wistar, and renewed in Baltimore, stemmed I think from the MSKCC/PPHM November SITC 2016 poster/abstract—that poster, explicitly, had little or nothing to do with CAR-T therapy then, did it?

The poster #1651 relating to PPHM, MSKCC and Bavi family role in CAR-T therapy first appeared at AACR 2017 in April.

I enjoy international chess matches. Your move.

So far, we are even—either alternative is possible for design of a human clinical trial.

BTW, I have a further observation gleaned from a different 2017 SITC poster that may be worth further discussion....later.

[keep_trying]

CP, Dr. Wolchak saying "that depends on the company" more likely is a generic reference. I will be delighted if a tech deal emerges before the January meeting. Yet, I guess that PPHM is setting up segregation of Avid bio mabufacturing with purpose. The stand still period lasts a year and stability occurs after directors are voted in place next month by shareholders. Cash drain stabilizes with Avid sales and R&D wind down over the same time period.

Best wishes and IMO.
KT

[biopharm]

I had to read that post again and timeline is reassuring as it shows the IP held by Peregrine likely nearing its end play

Matching that up against the pps being forced back down .....as now heading back to prior levels will hopefully show how desperate some party is to shake shares loose the last few days

Is Santa on his way and is the fat lady about to get on stage and prepare her voice for singing ....